Medications known as SGLT2 inhibitors have become widely used in recent years to treat people with type 2 diabetes. These drugs help lower blood sugar levels in a unique way.
Instead of only helping the body use insulin better, they work by helping the kidneys remove extra sugar from the body through urine. Because of this effect, many patients have been able to control their blood sugar more effectively with these medicines.
Type 2 diabetes is a long‑term condition that affects how the body processes sugar, also called glucose. When glucose builds up in the blood, it can damage many parts of the body over time, including the heart, kidneys, eyes, and nerves.
Doctors often prescribe medications to help keep blood sugar levels within a healthy range. Over the past decade, SGLT2 inhibitors have become an important option because they not only lower blood sugar but may also reduce the risk of heart disease and kidney problems in people with diabetes.
However, a recent investigation by the U.S. Food and Drug Administration, also known as the FDA, has raised concerns about a rare but very serious side effect linked to these medications. The study found that some patients taking SGLT2 inhibitors developed a dangerous infection called Fournier gangrene.
Fournier gangrene is extremely rare, but it is also life‑threatening if not treated quickly. The infection affects the soft tissue around the genital and anal area. Once it begins, it can spread very rapidly through the surrounding tissue. Without urgent treatment, the infection can become severe and may even lead to death.
The FDA decided to investigate this issue after receiving reports of patients who developed the infection while using SGLT2 inhibitors. The agency reviewed safety data on several different diabetes medications.
These included SGLT2 inhibitors, metformin, insulin, and combination drugs used to treat diabetes. The goal was to determine whether any of these medications were linked to serious health problems.
During their review, the FDA found a concerning pattern. Between March 2013 and January 2019, they identified 55 cases of Fournier gangrene in patients who were taking SGLT2 inhibitors. The patients ranged in age from 33 to 87 years old. Among them, 39 were men and 16 were women.
When the researchers compared these findings with other diabetes drugs, the difference was striking. Over a much longer period, from 1984 to early 2019, only 19 cases of the same infection were reported among people taking other types of diabetes medications.
Because the number of cases linked to SGLT2 inhibitors was much higher within a shorter time frame, the FDA believes the drugs may increase the risk of this rare infection.
The study also found that the infection could appear at very different times after starting the medication. Some patients developed Fournier gangrene only a few days after beginning treatment. Others developed it more than four years later.
This suggests that the risk may not be limited to the early stages of treatment and that patients may need long‑term monitoring.
In several cases, patients experienced additional serious health problems along with the infection. Some developed diabetic ketoacidosis, which is a dangerous condition where acids build up in the blood.
Others developed sepsis, a severe infection that spreads throughout the body, or kidney damage. These complications can make treatment even more difficult.
Fournier gangrene usually begins with symptoms such as pain, redness, or swelling in the genital or anal area. Patients may also develop fever, fatigue, or a general feeling of illness. Because the infection spreads quickly, early treatment is extremely important. Doctors often need to use strong antibiotics and, in many cases, surgery to remove infected tissue.
The findings of this study serve as an important warning for both doctors and patients. SGLT2 inhibitors, including medications such as canagliflozin, dapagliflozin, and empagliflozin, are effective treatments for many people with type 2 diabetes. They can help control blood sugar and may provide additional benefits for heart and kidney health.
However, patients and healthcare providers should be aware of the possible risks. Anyone taking these medications should pay close attention to unusual symptoms, especially pain, swelling, or redness in the genital area. If these symptoms appear, medical help should be sought immediately.
It is also important to remember that the infection occurred in both men and women and could happen even years after starting treatment. This means that awareness should remain high throughout the entire time a patient is using the medication.
At the same time, the FDA does not recommend that patients stop taking these drugs without speaking with their doctor. For many people, the benefits of SGLT2 inhibitors still outweigh the risks. The key is careful monitoring and clear communication between patients and healthcare providers.
Researchers are continuing to study why this infection occurs in some patients who take SGLT2 inhibitors. Understanding the exact cause may help doctors prevent the problem in the future or identify patients who may have a higher risk.
In the end, this study highlights an important truth about modern medicine. Even medications that provide strong benefits can sometimes carry unexpected risks. With careful monitoring, better awareness, and continued research, doctors can help ensure that diabetes treatments remain both effective and safe for patients.
If you care about diabetes, please read studies about a cure for type 2 diabetes, and these vegetables could protect against kidney damage in diabetes.
For more health information, please see recent studies about bone drug that could lower risk of type 2 diabetes, and results showing eating more eggs linked to higher risk of type 2 diabetes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
